Roles of healthcare professionals in the management of chronic gastrointestinal diseases with a focus on primary care: A systematic review
Background and aim Inflammatory bowel disease (IBD) refers to a group of complex and chronic conditions that requires long‐term care delivered by a group of healthcare professionals through a multidisciplinary care model. We conducted a systematic review to examine and understand the role of healthc...
Saved in:
Published in | JGH open Vol. 4; no. 2; pp. 221 - 229 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Melbourne
Wiley Publishing Asia Pty Ltd
01.04.2020
John Wiley & Sons, Inc Wiley |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background and aim
Inflammatory bowel disease (IBD) refers to a group of complex and chronic conditions that requires long‐term care delivered by a group of healthcare professionals through a multidisciplinary care model. We conducted a systematic review to examine and understand the role of healthcare professionals in the primary care management of IBD, and identify the gaps in IBD management that could be filled by primary care providers such as general practitioners (GPs) and pharmacists.
Methods
The search strategy retrieved published studies from five databases, and eligible articles were assessed for quality. A gray literature search of the websites of organizations was also undertaken.
Results
Twenty‐one studies were included, of which 19 were peer‐reviewed research articles and two reports were from organizational bodies. Although studies have shown the roles of GPs, pharmacists, dietitians, and psychologists in IBD management, nurses and gastroenterologists were the key drivers delivering specialized care to IBD patients. Many key services are accessible only for hospital inpatients (tertiary care) or through outpatient clinics (secondary care) with an absence of a multidisciplinary approach including GPs and pharmacists.
Conclusion
Gastroenterologists and nurses have an important role in the delivery of care to patients with chronic gastrointestinal diseases including IBD, coeliac disease, irritable bowel syndrome, and functional dyspepsia. The role of nurses includes provision of specialized care to IBD patients, as well as supportive care such as education, monitoring of therapy, and ongoing assistance. The available evidence shows many opportunities for primary care providers to play a more active role in the management of IBD patients.
Although the review showed the roles of general practitioners (GPs), pharmacists, dietitians, and psychologists in inflammatory bowel disease (IBD) management, nurses and gastroenterologists were the key drivers delivering specialized care to IBD patients. Many key services are accessible only for hospital inpatients (tertiary care) or through outpatient clinics (secondary care) with an absence of a multidisciplinary approach including GPs and pharmacists. The available evidence shows opportunities for primary care providers to play a more active role in the management of IBD patients. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Financial support: The authors received no financial support for the research, authorship, and/or publication of this article. Guarantor of the article: Marjorie M Walker. Declaration of conflict of interest: Simon Keely: Grant/research support: Cancer Institute NSW (Career Development Fellowship), National Health and Medical Research Council (Project Grant), Commonwealth Diagnostics International (biomarkers for FGIDs), Syntrix Biosystems (contract research—drug delivery). Anatara Lifesciences (Advisory Board/Funded research). Gossamer Bio (Advisory Board/Funded research). Nicholas J Talley:Grant/research support: Rome Foundation; Abbott Pharmaceuticals; Datapharm; Pfizer; Salix (irritable bowel syndrome); Prometheus Laboratories Inc. (Irritable bowel syndrome [IBS] Diagnostic); Janssen (constipation). Consultant/Advisory Boards: Allakos (IBS), Adelphi Values (functional dyspepsia [patient reported outcome measures]; [Budesonide]); GI therapies (chronic constipation [Rhythm IC]); Allergens PLC; Napo Pharmaceutical; Outpost Medicine; Samsung Bioepis; Yuhan (IBS); Synergy (IBS); Theravance (gastroparesis). Patent holder: Biomarkers of irritable bowel syndrome; Licensing Questionnaires (Mayo Clinic Talley Bowel Disease Questionnaire—Mayo Dysphagia Questionnaire); Nestec European Patent (Application No. 12735358.9); Singapore “Provisional” Patent (NTU Ref: TD/129/17 “Microbiota Modulation of BDNF Tissue Repair Pathway). Marjorie M Walker: Grant/research support: Prometheus Laboratories Inc. (Irritable bowel syndrome [IBS] Diagnostic), Commonwealth Diagnostics International (biomarkers for FGIDs). The authors declare that there is no conflict of interest. The authors alone are responsible for the content and writing of the article. Author contribution: Sharmila S Prasad, Simon Keely, Therése Kairuz, and Marjorie M Walker contributed to the study concept and design. Sharmila S Prasad searched the data. Sharmila S Prasad and Michael Potter collected and analyzed the data. Sharmila S Prasad, Marjorie M Walker, and Therése Kairuz drafted the initial manuscript. All authors (Sharmila S Prasad, Michael Potter, Marjorie M Walker, Simon Keely, Nicholas J Talley, and Therése Kairuz) approved the final version of the manuscript. |
ISSN: | 2397-9070 2397-9070 |
DOI: | 10.1002/jgh3.12235 |